Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Dendreon: 3 Key Factors to Know

In the following video, Fool analysts David Williamson and Austin Smith discuss Dendreon (NASDAQOTH: DNDNQ  ) and some areas investors need to watch.

For health-care investors, Dendreon was one of the most exciting stocks of 2012, and it may be for 2013 as well, Austin says. But the microcap biotech landscape can be pretty tough for individual investors to navigate.

For a one-trick pony like Dendreon, the company's short-, mid-, and long-term hopes all rest on its prostate-cancer treatment, Provenge, David says.

Investors can think of it a bit like a retail company. A company can keep growing by adding stores, but the best measure of success is its same-store sales.

Since the start of 2013, Dendreon has seen sales at its existing sites go from decelerating to declining. That means doctors may not be seeing enough benefit in the drug to keep prescribing it, David says.

Dendreon has also been restructuring after building three plants to make a product for which demand never materialized. It has closed one of those, and investors will want to watch for additional cost-cutting measures in the coming quarters.

And finally, a large debt payment looms in 2016, and it could be a challenge for Dendreon to meet that payment, David says.

Dendreon's run over the past four years has seen sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine, Provenge, became a lightning rod for debate. But where does that leave investors -- other than a bit nauseous from the roller-coaster ride? Our own David Williamson answers this question, and many more, inside our brand-new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2192897, ~/Articles/ArticleHandler.aspx, 9/25/2016 11:59:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
JNJ $118.81 Down -0.65 -0.54%
Johnson and Johnso… CAPS Rating: *****
MDVN $81.42 Up +0.34 +0.42%
Medivation CAPS Rating: ****